Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Lancet Oncol
; 19(1): 139-148, 2018 01.
Article
in En
| MEDLINE
| ID: mdl-29174310
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quinazolines
/
Vinblastine
/
Antineoplastic Combined Chemotherapy Protocols
/
Biomarkers, Tumor
/
Cisplatin
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
ErbB Receptors
/
Lung Neoplasms
/
Mutation
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Country/Region as subject:
Asia
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2018
Document type:
Article
Affiliation country:
China
Country of publication:
Reino Unido